Abstract
EGFR, BRAF, PIK3CA, and KRAS genes play major roles in EGFR pathway, and accommodate activating mutations that predict response to many targeted therapeutics. However, connections between these mutations and EGFR pathway expression patterns remain unexplored. Here, we investigated transcriptomic associations with these activating mutations in three ways. First, we compared expressions of these genes in the mutant and wild type tumors, respectively, using RNA sequencing profiles from The Cancer Genome Atlas project database (n = 3660). Second, mutations were associated with the activation level of EGFR pathway. Third, they were associated with the gene signatures of differentially expressed genes from these pathways between the mutant and wild type tumors. We found that the upregulated EGFR pathway was linked with mutations in the BRAF (thyroid cancer, melanoma) and PIK3CA (breast cancer) genes. Gene signatures were associated with BRAF (thyroid cancer, melanoma), EGFR (squamous cell lung cancer), KRAS (colorectal cancer), and PIK3CA (breast cancer) mutations. However, only for the BRAF gene signature in the thyroid cancer we observed strong biomarker diagnostic capacity with AUC > 0.7 (0.809). Next, we validated this signature on the independent literature-based dataset (n = 127, fresh-frozen tissue samples, AUC 0.912), and on the experimental dataset (n = 42, formalin fixed, paraffin embedded tissue samples, AUC 0.822). Our results suggest that the RNA sequencing profiles can be used for robust identification of the replacement of Valine at position 600 with Glutamic acid in the BRAF gene in the papillary subtype of thyroid cancer, and evidence that the specific gene expression levels could provide information about the driver carcinogenic mutations.
Similar content being viewed by others
Data Availability
Transcriptomic data used for experimental validation of gene signatures were deposited to the Gene Expression Omnibus database (GEO) under accession no. GSE138042. Raw FASTQ data are available in the SRA archive under accession no. PRJNA588725. Description of the clinically relevant (age, sex, diagnosis, tumor histotype, BRAFV600E mutation status) and technical (RIN, date of sequencing) information is given in the Table S1 in the Supplement.
Abbreviations
- BC:
-
breast cancer
- CRC:
-
colorectal cancer
- LA:
-
lung adenocarcinoma
- TC:
-
thyroid cancer
References
Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., and Ueno, N. T. (2021) Role of epidermal growth factor receptor in breast cancer, Breast Cancer Res. Treat., 136, 331-345.
Bardeesy, N., Kim, M., Xu, J., Kim, R.-S., Shen, Q., et al. (2005) Role of epidermal growth factor receptor signaling in RAS-driven melanoma, Mol. Cell. Biol., 25, 4176-4188, https://doi.org/10.1128/mcb.25.10.4176-4188.2005.
Zhou, C., and Yao, L. (2016) Di Strategies to improve outcomes of patients with EGRF-Mutant Non-Small cell lung cancer: review of the literature, J. Thorac. Oncol., 11, 174-186.
Greaves, W. O., Verma, S., Patel, K. P., Davies, M. A., Barkoh, B. A., et al. (2013) Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma, J. Mol. Diagnostics, 15, 220-226, https://doi.org/10.1016/j.jmoldx.2012.10.002.
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., et al. (2015) Genomic classification of cutaneous melanoma, Cell, 161, 1681-1696, https://doi.org/10.1016/j.cell.2015.05.044.
Kebebew, E., Weng, J., Bauer, J., Ranvier, G., Clark, O. H., et al. (2007) The prevalence and prognostic value of BRAF mutation in thyroid cancer, Ann. Surg., 246, 466-470, https://doi.org/10.1097/SLA.0b013e318148563d.
Holderfield, M., Deuker, M. M., McCormick, F., McMahon, M. (2014) Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond, Nat. Rev. Cancer, 14, 455-467.
Silva, J. M., Bulman, C., and McMahon, M. (2014) BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation, Mol. Cancer Res., 12, 447-463, https://doi.org/10.1158/1541-7786.MCR-13-0224-T.
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., et al. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer, Gene, 366, 2-16.
Frampton, J. E. (2010) Cetuximab: a review of its use in squamous cell carcinoma of the head and neck, Drugs, 70, 1987-2010.
Messersmith, W. A., and Ahnen, D. J. (2008) Targeting EGFR in colorectal cancer, N. Engl. J. Med., 359, 1834-1836.
Alexander, M., Lin, E., and Cheng, H. (2020) Leptomeningeal metastases in non-small cell lung cancer: optimal systemic management in NSCLC with and without driver mutations, Curr. Treat. Options Oncol., 21, 72, https://doi.org/10.1007/s11864-020-00759-3.
Garg, A., Batra, U., Choudhary, P., Jain, D., Khurana, S., et al. (2020) Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: a real-world multicentric cohort analysis from India, Curr. Probl. Cancer, 44, 100570, https://doi.org/10.1016/j.currproblcancer.2020.100570.
Lazzari, C., Gregorc, V., Karachaliou, N., Rosell, R., Santarpia, M. (2020) Mechanisms of resistance to osimertinib, J. Thorac. Dis., 12, 2851-2858, https://doi.org/10.21037/jtd.2019.08.30.
Odogwu, L., Mathieu, L., Blumenthal, G., Larkins, E., Goldberg, K. B., et al. (2018) FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations, Oncologist, 23, 740-745, https://doi.org/10.1634/theoncologist.2017-0642.
Kim, G., McKee, A. E., Ning, Y. M., Hazarika, M., Theoret, M., et al. (2014) FDA approval summary: Vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation mutation, Clin. Cancer Res., 20, 4994-5000, https://doi.org/10.1158/1078-0432.CCR-14-0776.
Tang, K. T., and Lee, C. H. (2010) BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications, J. Chinese Med. Assoc., 73, 113-128.
Narayan, P., Prowell, T. M., Gao, J. J., Fernandes, L. L., Li, E., et al. (2020) FDA Approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer, Clin. Cancer Res., 27, 1842-1849, https://doi.org/10.1158/1078-0432.ccr-20-3652.
Rodon, J., Soria, J. C., Berger, R., Miller, W. H., Rubin, E., et al. (2019) Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial, Nat. Med., 25, 751-758, https://doi.org/10.1038/s41591-019-0424-4.
Poddubskaya, E., Sorokin, M., Garazha, A., Glusker, A., Moisseev, A., et al. (2020) Clinical use of RNA sequencing and oncobox analytics to predict personalized targeted therapeutic efficacy, J. Clin. Oncol., 38, e13676, https://doi.org/10.1200/jco.2020.38.15_suppl.e13676.
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018) Integrating single-cell transcriptomic data across different conditions, technologies, and species, Nat. Biotechnol., 36, 411-420, https://doi.org/10.1038/nbt.4096.
Buzdin, A., Sorokin, M., Garazha, A., Sekacheva, M., Kim, E., et al. (2018) Molecular pathway activation – new type of biomarkers for tumor morphology and personalized selection of target drugs, Semin. Cancer Biol., 53, 110-124.
Borisov, N., Sergeeva, A., Suntsova, M., Raevskiy, M., Gaifullin, N., et al. (2021) Machine learning applicability for classification of PAD/VCD chemotherapy response using 53 multiple myeloma RNA sequencing profiles, Front. Oncol., 11, 652063, https://doi.org/10.3389/fonc.2021.652063.
Borisov, N. M., Terekhanova, N. V., Aliper, A. M., Venkova, L. S., Smirnov, P. Y., et al. (2014) Signaling pathways activation profiles make better markers of cancer than expression of individual genes, Oncotarget, 5, 10198-10205, https://doi.org/10.18632/oncotarget.2548.
Borisov, N., Suntsova, M., Sorokin, M., Garazha, A., Kovalchuk, O., et al. (2017) Data aggregation at the level of molecular pathways improves stability of experimental transcriptomic and proteomic data, Cell Cycle, 16, 1810-1823, https://doi.org/10.1080/15384101.2017.1361068.
Tsimberidou, A. M., Fountzilas, E., Bleris, L., and Kurzrock, R. (2020) Transcriptomics and solid tumors: the next frontier in precision cancer medicine, Semin. Cancer Biol., https://doi.org/10.1016/j.semcancer.2020.09.007.
Petrov, I., Suntsova, M., Ilnitskaya, E., Roumiantsev, S., Sorokin, M., et al. (2017) Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas, Oncotarget, 8, 83768-83780, https://doi.org/10.18632/oncotarget.19662.
Yoo, S. K., Lee, S., Kim, S. J., Jee, H. G., Kim, B. A., et al. (2016) Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers, PLoS Genet., 12, e1006239, https://doi.org/10.1371/journal.pgen.1006239.
Titov, S. E., Ivanov, M. K., Karpinskaya, E. V., Tsivlikova, E. V., Shevchenko, S. P., et al. (2016) miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors, BMC Cancer, 16, 201, https://doi.org/10.1186/s12885-016-2240-2.
Suntsova, M., Gaifullin, N., Allina, D., Reshetun, A., Li, X., et al. (2019) Atlas of RNA sequencing profiles for normal human tissues, Sci. Data, 6, 1-9, https://doi.org/10.1038/s41597-019-0043-4.
Amin, S. B., Yip, W. K., Minvielle, S., Broyl, A., Li, Y., et al. (2014) Gene expression profile alone is inadequate in predicting complete response in multiple myeloma, Leukemia, 28, 2229-2234, https://doi.org/10.1038/leu.2014.140.
Boratyn, G. M., Thierry-Mieg, J., Thierry-Mieg, D., Busby, B., and Madden, T. L. (2019) Magic-BLAST, an accurate RNA-seq aligner for long and short reads, BMC Bioinformatics, 20, 405, https://doi.org/10.1186/s12859-019-2996-x.
Zhao, Y., Wong, L., and Goh, W. W. B. (2020) How to do quantile normalization correctly for gene expression data analyses, Sci. Rep., 10, 1-11, https://doi.org/10.1038/s41598-020-72664-6.
Huang, X., Stern, D. F., and Zhao, H. (2016) Transcriptional profiles from paired normal samples offer complementary information on cancer patient survival – evidence from TCGA pan-cancer data, Sci. Rep., 6, 1-9, https://doi.org/10.1038/srep20567.
BioCarta – Online maps of metabolic and signaling pathways|HSLS Available online, URL: https://www.hsls.pitt.edu/obrc/index.php?page=URL1151008585.
egf signaling – GeneGlobe, Available online, URL: https://geneglobe.qiagen.com/us/explore/pathway-details/egf-signaling.
Buzdin, A. A., Sorokin, M., Borisov, N. M., Kuzmin, D., Gudkov, A., et al. (2021) Algorithmic annotation of functional roles for components of 3044 human molecular pathways, Front. Genet., 12, 139, https://doi.org/10.3389/FGENE.2021.617059.
Sorokin, M., Kholodenko, R., Suntsova, M., Malakhova, G., Garazha, A., et al. (2018) Oncobox bioinformatical platform for selecting potentially effective combinations of target cancer drugs using high-throughput gene expression data, Cancers (Basel), 10, 365, https://doi.org/10.3390/cancers10100365.
Vladimirova, U., Rumiantsev, P., Zolotovskaia, M., Albert, E., Abrosimov, A., et al. (2021) DNA repair pathway activation features in follicular and papillary thyroid tumors, interrogated using 95 experimental RNA sequencing profiles, Heliyon, 7, e06408, https://doi.org/10.1016/j.heliyon.2021.e06408.
Lokhandwala, P. M., Tseng, L. H., Rodriguez, E., Zheng, G., Pallavajjalla, A., et al. (2019) Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing, BMC Cancer, 19, 665, https://doi.org/10.1186/s12885-019-5864-1.
Hong, W., Wu, Q., Zhang, J., and Zhou, Y. (2019) Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer, Oncol. Lett., 18, 3887-3895, https://doi.org/10.3892/ol.2019.10715.
Gilson, P., Franczak, C., Dubouis, L., Husson, M., Rouyer, M., et al. (2019) Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation, PLoS One, 14, e0219204, https://doi.org/10.1371/journal.pone.0219204.
Martínez-Saéz, O., Chic, N., Pascual, T., Adamo, B., Vidal, M., et al. (2020) Frequency and spectrum of PIK3CA somatic mutations in breast cancer, Breast Cancer Res., 22, 45, https://doi.org/10.1186/s13058-020-01284-9.
Kamashev, D., Sorokin, M., Kochergina, I., Drobyshev, A., Vladimirova, U., et al. (2020) Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth, Heliyon, 7, e06394, https://doi.org/10.1016/j.heliyon.2021.e06394.
Blighe, K., and Rana, S., and Lewis, M. (2021) EnhancedVolcano: publication-ready volcano plots with enhanced colouring and labeling, URL: https://bioconductor.org/packages/release/bioc/vignettes/EnhancedVolcano/inst/doc/EnhancedVolcano.html#references.
Crispo, F., Notarangelo, T., Pietrafesa, M., Lettini, G., Storto, G., et al. (2019) Braf inhibitors in thyroid cancer: clinical impact, mechanisms of resistance and future perspectives, Cancers (Basel), 11, 1388, https://doi.org/10.3390/cancers11091388.
Borisov, N., Sorokin, M., Tkachev, V., Garazha, A., and Buzdin, A. (2020) Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments, BMC Med. Genomics, 13, 111, https://doi.org/10.1186/s12920-020-00759-0.
Boyd, J. C. (1997) Mathematical tools for demonstrating the clinical usefulness of biochemical markers, Scand. J. Clin. Invest. Suppl., 227, 46-63.
Wong, D. J. L., and Ribas, A. (2016) Targeted therapy for melanoma, in Cancer Treatment and Research, Kluwer Academic Publishers, Vol. 167, pp. 251-262.
Hou, J., Wang, Z., Li, H., Zhang, H., and Luo, L. (2020) Gene signature and identification of clinical trait-related m6A regulators in pancreatic cancer, Front. Genet., 11, 522, https://doi.org/10.3389/fgene.2020.00522.
Funding
This study was financially supported by the Russian Science Foundation (project no. 18-15-00061).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
he authors Mikhail Raevskiy, Andrew Garazha, and Anton Buzdin are employed by the company OmicsWay Corp., and Maxim Sorokin is employed by the company Oncobox Ltd. The remaining authors had only academic affiliations. All the authors declare no conflicts of interest. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Electronic supplementary material
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Raevskiy, M., Sorokin, M., Vladimirova, U. et al. EGFR Pathway-Based Gene Signatures of Druggable Gene Mutations in Melanoma, Breast, Lung, and Thyroid Cancers. Biochemistry Moscow 86, 1477–1488 (2021). https://doi.org/10.1134/S0006297921110110
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0006297921110110